CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 129869-130078 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/038354e8830fe01feb621a12e8a8c467a15b6354","sourcedb":"CORD-19","sourceid":"038354e8830fe01feb621a12e8a8c467a15b6354","text":"The overall tolerance profile was favorable, and an independent Experts Board recommended that clinical development should be continued, but with increased safety documentation in the phase III efficacy study.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T797","span":{"begin":0,"end":209},"obj":"Sentence"},{"id":"T6827","span":{"begin":0,"end":209},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T797","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T6827","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"Epistemic_Statements","denotations":[{"id":"T315","span":{"begin":0,"end":209},"obj":"Epistemic_statement"}],"attributes":[{"subj":"T315","pred":"source","obj":"Epistemic_Statements"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T202","span":{"begin":0,"end":209},"obj":"Sentence"}],"attributes":[{"subj":"T202","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T702","span":{"begin":30,"end":33},"obj":"Disease"}],"attributes":[{"id":"A702","pred":"mondo_id","subj":"T702","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"subj":"T702","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#cf93ec","default":true},{"id":"Epistemic_Statements","color":"#93ecb5"},{"id":"CORD-19_Custom_license_subset","color":"#ec9b93"},{"id":"CORD-19-PD-MONDO","color":"#93a5ec"}]}]}}